[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576472":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":32,"locations":41,"responsibleParty":96,"collaborators":99,"id":102,"slug":10,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":10,"studyType":115,"phases":10,"briefSummary":116,"conditions":117,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Statin continued",null,"Patients in which the statin was continued after the index event",[13],"Drug: Statin",{"label":15,"type":10,"description":16,"interventionNames":10},"Statin discontinued","Patients in which the statin was discontinued after the index event",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Statin","Statin use",[9],[24],"atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin",[26,30],{"name":27,"affiliation":28,"role":29},"Renske van den Berg-Vos, Prof. dr.","Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"Nathalie van der Velde, Prof. dr.",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Susanna R Prins, MSc","CONTACT","0031 20 566 9111","s.r.prins@amsterdamumc.nl",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":40},"Birgit A Damoiseaux-Volman, PhD","b.a.damoiseaux@amsterdamumc.nl",[42,58,70,83],{"facility":43,"status":44,"city":45,"state":10,"zip":10,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Flevoziekenhuis","RECRUITING","Almere Stad","Netherlands",{"type":48,"coordinates":49},"Point",[50,51],5.21413,52.37025,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":56,"phoneExt":10,"email":57},"Elizabeth Osei, MD, PHD","0031368688720","losei@flevoziekenhuis.nl",{"facility":59,"status":44,"city":60,"state":10,"zip":10,"country":46,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Amsterdam UMC, location AMC","Amsterdam",{"type":48,"coordinates":62},[63,64],4.88969,52.37403,{"lat":64,"lon":63},[67],{"name":68,"role":35,"phone":69,"phoneExt":10,"email":37},"Susanna Prins, MD","0031205669111",{"facility":71,"status":44,"city":72,"state":10,"zip":10,"country":46,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Catharina Ziekenhuis","Eindhoven",{"type":48,"coordinates":74},[75,76],5.47778,51.44083,{"lat":76,"lon":75},[79],{"name":80,"role":35,"phone":81,"phoneExt":10,"email":82},"Rob Gons, MD, PHD","031402399426","rob.gons@catharinaziekenhuis.nl",{"facility":84,"status":44,"city":85,"state":10,"zip":10,"country":46,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Isala Klinieken","Zwolle",{"type":48,"coordinates":87},[88,89],6.09444,52.5125,{"lat":89,"lon":88},[92],{"name":93,"role":35,"phone":94,"phoneExt":10,"email":95},"Wilmar Jolink, MD, PHD","0031886242461","w.m.t.jolink@isala.nl",{"type":29,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":59,"oldNameTitle":10,"oldOrganization":10},"Prof. dr. Nathalie van der Velde","Professor dr. Nathalie van der Velde, Full Professor Geriatric medicine (internal medicine)",[100],{"name":101,"class":6},"VU University of Amsterdam","100576472",false,"NCT06785740","Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study","SAFEST-coh","Inclusion Criteria:\n\n* age = 70 years or older at the time of ischemic stroke or TIA;\n* inclusion within 6 weeks after diagnosis of ischemic stroke or TIA;\n* already using statin therapy at the time of the index event;\n* frailty as defined by a pre-event score of 4-7 and\u002For post-event score of 6-7 on the validated Clinical Frailty Scale.\n\nExclusion Criteria:\n\n* Previous serious adverse drug reactions (defined as an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisa-tion, results in persistent or significant disability or incapacity, or is a birth defect32) to statins or other contraindications to statin use.\n* Very severe frailty or very limited life expectancy (\\\u003C 6 months) as defined by a score \\>= 8 points on the validated Clinical Frailty Scale.\n* Inability to communicate in Dutch.\n* Inability to respond to questions, either independently or with the assistance of a proxy.\n* Inability or unwillingness to provide written informed consent, either independently or with the assistance of a proxy.","ALL","70 Years","120 Years",{"count":113,"type":114},300,"ESTIMATED","OBSERVATIONAL","Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST-cohort, the investigators will assess the impact of continuing versus discontinuing a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and MACE free survival during a two-year follow-up period.",[118,119],"Ischemic Stroke","TIA","2025-01-19",{"date":122,"type":123},"2025-01-21","ACTUAL",{"date":125,"type":123},"2024-11-01",{"date":127,"type":114},"2029-09",{"name":5,"class":6},4]